Neuberger Berman Group LLC Seagen Inc. Transaction History

Neuberger Berman Group LLC

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 14, 2023	SELL	$191.51 - $216.16 $7.36 Million - $8.3 Million	-38,406 Reduced 43.07%	50,763 $10.8 Million
Q2 2023 Aug 11, 2023	SELL	$187.64 - $206.25 $2.76 Million - $3.03 Million	-14,701 Reduced 14.15%	89,169 $17.2 Million
Q1 2023 May 12, 2023	SELL	$127.59 - $203.08 $10.7 Million - $17 Million	-83,577 Reduced 44.59%	103,870 $21 Million
Q4 2022 Feb 13, 2023	BUY	$117.37 - $139.17 $136,383 - $161,715	1,162 Added 0.62%	187,447 $24.1 Million
Q3 2022 Nov 15, 2022	BUY	$135.27 - $180.11 $73,857 - $98,340	546 Added 0.29%	186,285 $25.5 Million
Q2 2022 Aug 15, 2022	BUY	$108.81 - $179.33 $982,119 - $1.62 Million	9,026 Added 5.11%	185,739 $32.9 Million
Q1 2022 May 13, 2022	BUY	$119.61 - $157.85 $156,689 - $206,783	1,310 Added 0.75%	176,713 $25.5 Million
Q4 2021 Feb 11, 2022	BUY	$142.57 - $190.86 $2.51 Million - $3.37 Million	17,634 Added 11.18%	175,403 $27.1 Million
Q3 2021 Nov 12, 2021	BUY	$142.45 - $169.82 $22.5 Million - $26.8 Million	157,769 New	157,769 $26.8 Million

1.26M

23K

55.2K

Ticker SGEN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 185,664,992
Description
Seagen Inc., a biotechnology company, develops and commercializes therapies for the treatment of cancer in the United States and internationally. The company offers ADCETRIS, an antibody-drug conjugate (ADC) for the treatment of patients with Hodgkin lymphoma or CD30-positive T-cell lymphomas; PADCEV, an ADC targeting Nectin-4 for the treatment ...

Get notified when there are updates to the investment portfolio of Neuberger Berman Group LLC, based on Form 13F filings with the SEC.

Stay updated on Neuberger Berman Group LLC with notifications on news.